Putative receptors for arginine8-vasopressin (AVP) in rat brain were localized and characterized using autoradiographic and radioligand-binding techniques. When brain slices were incubated with tritium-labeled vasopressin, an intense concentration of binding sites was identified which included the medial aspects of the amygdala. Binding of labeled AVP to membrane preparations from this brain region was saturable, specific, reversible, and of high affinity. An antagonist of the peripheral pressor activity of vasopressin was found to be a potent competitor for binding to this site.
Arginine'-vasopressin (AVP) is synthesized in hypothalamic neurons which project to the posterior pituitary, as well as to numerous extrahypothalamic brain regions (Farrell et al., 1968; Sterba, 1974; Kozlowski et al., 1976; Swanson, 1977; Buijs et al., 1978; Sofroniew and Weindl, 1982) . AVP has been extracted, measured, and chromatographically identified (Glick and Brownstein, 1980; Dorsa and Bottemiller, 1982,1983) in extrahypothalamic brain tissue.
Central administration of AVP has been reported to influence the regulation of blood pressure (Matsuguchi et al., 1980; Pittman et al., 1982) and body temperature (Kasting et al., 1980) , to facilitate memory (dewied, 1977; Van Ree et al., 1978; Kovacs et al., 1979; Koob et al., 1981) and the development of tolerance phenomena (Van Ree et al., 1978) , to alter turnover of other CNS transmitters (Tanaka et al., 1977) , and to modulate their neurochemical effects (Courtney and Raskind, 1983 total, a large body of evidence has been accumulating which supports the hypothesis that AVP or a related peptide is a neurotransmitter or neuromodulatory substance. However, until recently, little direct evidence for the existence of receptors for vasopressin in brain tissue has been reported. We have recently presented autoradiographic evidence of the existence of AVP-specific binding sites in the septum (Baskin et al., 1983; van Leeuwen and Wolters, 1983) and ventral forebrain (Baskin et al., 1983) and in the nucleus of the solitary tract (Dorsa et al., 1983) of the rat brain. Yamamura et al. (1983) have also reported AVP-binding sites in the magnocellular nuclei of the hypothalamus. Preliminary reports of AVP-binding sites in subcellular particulate fractions (Pearlmutter et al., 1983) and membrane preparations (Dorsa et al., 1983) obtained from various brain regions have recently appeared. In the present study, we report localization of AVP-binding sites in amygdalar region of the rat brain and characterization of an AVPspecific receptor in membrane preparations from this region of the brain.
Materials and Methods
Preparation of brain tissue slices. Long-Evans rats (180 to 200 gm) were sacrificed by decapitation, and their brains were rapidly removed, mounted on brass cryostat tissue platforms, and then frozen on CO-ice. Serial cryostat sections (10 pm) were thaw mounted on gelatincoated microscope slides (Young and Kuhar, 1979; Herkenham and Pert, 1982) with adjacent serial sections mounted on separate slides. The slides were then frozen at -70°C and stored (2 to 3 weeks maximum) until use. AVP binding to tissue slices. For assays of binding of avp to tissue slices, slides containing tissue slices were thawed to room temperature and placed flat on moist paper towels in a plastic tray. The tissue slices were covered with 200 ~1 of incubation medium containing 100 mM Tris-HCl, pH 8.0, 10 mg of MgCIB, 1% bovine serum albumin, 0.5 mg/ml of bacitracin, and 100 kallikrine inhibitory units (KIU)/ml of aprotinin (Sigma) (Dorsa et al., 1983) . The incubation medium contained 5 x lo-' M [3H]arginine8-vasopressin ([3H]AVP) (specific activity 42.1 Ci/mmol, New England Nuclear) or a mixture of [3H]AVP and 1 X 10m6 M unlabeled AVP. The trays were covered during incubation to minimize evaporation and were incubated at room temperature for 30 min. Time course studies had shown that maximum specific binding occurs by 30 min. Slides were then individually drained of excess incubation medium by tilting them and allowing incubation medium to run onto the towel. They were then placed in plastic slide racks and transferred sequentially through two buffer rinses of 30 set each. The rinse consisted of 10 mM Tris-HCl, pH 8.0,l mM MgCl*, and 0.1% bovine serum albumin at 0°C. Slide-mounted tissue sections were immediately prepared for autoradiography by drying the sections with a stream of cool air and were stored in a vacuum desiccator at 0°C for 24 hr. Sections were then placed in contact with tritium-sensitive LKB Ultrofilm in an x-ray cassette, exposed for 1 month at 22°C and developed in D-19 for 4 min.
Membrane preparations. Brains were rapidly removed from 120 decapitated 2-month-old Sprague-Dawley rats and placed in ice-cold 1.0 mM Tris-HCl, 2.0 mM MgCl,, 1.0 mM dithiothreitol (DTT), 0.1 mM phenylmethylsulfonylfluoride (PMSF), pH 7.4. Tissue, including the amygdala and surrounding cortical structures, was removed and was separated randomly into four groups. Tissue was homogenized with a Tekmar (model SDT) homogenizer at a setting of 80 for 4 sec. The resulting homogenate was centrifuged at 600 x g for 10 min, and the pellet was discarded. The supernatant was centrifuged at 30,000 X g for 20 min, and the pellet, a partially purified membrane preparation, was washed and centrifuged a second time. The membranes were then resuspended in 0.25 M sucrose, 50 mM Tris-HCl, 1.0 mM DTT, 0.1 mM PMSF, pH 7.4, quick frozen in liquid nitrogen, and stored at -80°C. Under these conditions, the ["HI AVP-binding site was stable for up to 6 months, with no loss of specific binding compared to fresh membranes. Protein was determined by the method of Bradford (1976) with bovine serum albumin as the standard.
r3HJA VP-binding assay in membrane preparations. The ["HIAVP-binding assays were performed at a volume of 250 ~1 in polypropylene tubes (12 x 75 mm).
[3H] AVP was diluted in 236 mM NaCl, 10 mM KCl, 10 mM MgC12, 2 mM EGTA, 20 mM HEPES, pH 7.4, containing 20% ethanol and 10 mg/ml of bovine serum albumin and was added to assay tubes in a 25-~1 volume. Peptides were prepared in the same buffer, with the ethanol omitted. These solutions were added to assay tubes in 25-~1 volumes. Bacitracin (1.0 mg/ml) and aprotinin (2000 KIU/ml) were added in a lo-p1 volume. Partially purified membrane preparations, suspended in 236 mM NaCl, 10 mM KCl, 10 mM MgC12, 20 mM HEPES, pH 7.4, were added to assay tubes in a 190-CL1 volume to initiate the assay. The incubation was carried out at 25°C for 45 min and was terminated by the addition of 5 ml of 236 mM NaCl, 10 mM KCl, 10 mM MgCl*, 20 mM HEPES, pH 7.4, were added to assay tubes in a 190 /*l volume to initiate the assay. The incubation was carried out at 25°C for 45 min and was terminated by the addition of 5 ml of 236 mM NaCl, 10mM KCl, 10 mM MgC12, 2 mM EGTA, 20 mM HEPES, pH 7.4, at 4°C. The contents of the tubes were filtered immediately through Whatman GF/ C glass fiber filters on a Yeda filtration manifold. Filters were presoaked in buffer containing 10 nM AVP. Filters were washed with an additional 15 ml of buffer, dried by high vacuum, and placed in scintillation vials containing Hydrofluor (National Diagnostics). Radioactivity was determined by liquid scintillation counting (Packard model 460C) at 26% efficiency. Data analysis. Data derived from saturation experiments was analyzed using the nonlinear model fitting program LIGAND (Munson and Rodbard, 1980) to arrive at estimates for the following parameters: dissociation constant, binding site concentration, and nonspecific binding. Inhibitory constants (KL) were calculated from the formula I-& = I&,,/(1 + (AVP)/&) described by Cheng and Prusoff (1973) . The I&, is defined as the concentration of peptide that reduces specific bound [3H] AVP by 50%, (AVP) is the concentration of [3H]AVP in the assay tube, Kd is the [3H]AVP dissociation constant determined from saturation experiments. All data are reported as means + SE.
Results
Localization of QHIAVP binding. Figure 1 shows the results obtained on tritium-sensitive film exposed to brain slices which had been incubated with 5 nM [3H] AVP. In sections between 4 and 5 mm anterior to the vertical zero plane of Pelligrino et al. (1981) , an intense concentration of binding sites was apparent in the region of the amygdala. These binding sites were evident primarily in the central nucleus, medial nucleus, and in other sections (not shown), which also included the basolateral nucleus of the amygdala. Addition of 5 PM unlabeled AVP to the incubation medium abolished binding of ["HIAVP to the amygdala.
Binding kinetics.
["HIAVP bound rapidly to amygdala membranes, reaching equilibrium within 30 min at 25"C, and binding was stable for at least 30 min (Fig. 2) . The observed rate constant (K& was calculated to be 0. Pelligrino et al. (1981) (-0.6 mm from bregma). Selected features of the amygdala and other structures are shown. C, corpus callosum; Cl, internal capsule; OT, optic tract; CPU, caudate-putamen; AME, medial nucleus of the amygdala; AL, lateral nucleus; ACE, central nucleus; ABL, lateral part of the basal nucleus. The region of highest specific AVP binding is depicted in the half-tone.
half-time of dissociation of approximately 25 min at 25°C and 10 min at 37°C following a loo-fold dilution (Fig. 3) . The dissociation of [3H]AVP was not affected by the presence of unlabeled AVP (10 nM) in the dilution buffer (Fig. 3) . The calculated dissociation rate constant (K,,) at 25°C was 0.071 & 0.02 mine1 (n = 3). Using the association rate constant (K,,) and K,ff (see legends to Figs. 2 and 3 for explanation of calculations) we calculated a dissociation constant (I&) of 0.15 nM, which is in good agreement with the dissociation constant determined from equilibrium experiments (see below).
Binding site saturation. Binding of [3H]AVP to amygdala membranes was linear with respect to protein over a range of 125 to 375 pg of protein/assay tube (Fig. 4) . Analysis of saturation data with ligand (Munson and Rodbard, 1980) resulted in a best fit with a single site model (Fig. 5) (Fig. 6, Table I ).
Discussion
While a large body of evidence has been accumulating that vasopressin is a CNS transmitter or neuromodulator, the presence of putative receptors for AVP in brain (K,,) determined in a separate experiment (see Fig. 2 ) was used to solve the above equation for the rate constant of association (K,,) (Williams and Lefkowitz, 1978) .
tissue has only recently been reported. Autoradiographic evidence for the existence of AVP-specific binding sites in the septum and ventral forebrain (Baskin et al., 1983; van Leeuwen and Wolters, 1983) , in the nucleus of the solitary tract (Dorsa et al., 1983) , and in the magnocellular areas of the hypothalamus (Yamamura et al., 1983) of the rat brain has recently appeared. These areas are known to contain either cell bodies or fibers of neurons which immunostain for AVP or its neurophysin (Farrell et al., 1968; Sterba, 1974; Kozlowski et al., 1976; Swanson, 1977; Buijs et al., 1978; Sofroniew and Weindl, 1982) . Vasopressin-like immunoreactivity also is measurable by radioimmunoassay in extracts of these microdissected areas (Dorsa and Bottemiller, 1982, 1983) .
In the present study, we have provided evidence for the existence of high affinity receptors for AVP and related peptides in membranes prepared from brain tissue which included the amygdala and surrounding cortical structures.
[3H]AVP binding to brain tissue slices was highly localized to the medial aspects of the amygdala, a parallel distribution to that reported for AVPneurophysin-containing neurons (Buijs et al., 1978; Sofroniew and Weindl, 1982) .
Binding of ["HIAVP to membrane preparations which included amygdalar tissue was found to be saturable and of high affinity. The dissociation constant observed in brain tissue is slightly lower than that which we have measured in rat kidney (e.g., 1 to 3 nM) (Dorsa et al., 1983) , and well below the reported Kd for AVP receptors from rat vascular smooth muscle (e.g., 5 nM) (Schiffrin and Genest, 1983) . Michell et al. (1979) proposed two isotypes of the vasopressin receptor termed VI and V2. VI receptors were associated with calcium as a second messenger, while V, receptors were associated with cyclic AMP as a second messenger. The AVP receptor in renal tissue appears to be linked to adenylate cyclase (Bockaert et al., 1973; Butlen et al., 1978; Sawyer et al., 1981a; Dorsa et al., 1983) , while hepatic AVP receptors are not (Michell et al., 1979; Jard, 1983) . In addition, differences exist in potency of synthetic vasopressin agonists and antagonists that preferentially act as either pressor agents (Sawyer et al., 1981) or as antidiuretic agents (Butlen et al., 1978; Sawyer et al., 1982b; Crause and Fahrenholz, 1982) .
In the present study, we have identified a putative AVP receptor in brain tissue which appears to differ from the renal AVP receptor in specificity. In the amygdala, the pressor antagonist M-AVP (Kruszynski et al., 1980) was even more potent than synthetic AVP in displacing [3H]AVP from binding, whereas it is much less potent than AVP at the renal receptor when evaluated on tissue slice or membrane preparations (Dorsa et al., 1983) . In addition, we (Dorsa et al., 1983) and others (Courtney and Raskind, 1983) have recently reported that AVP fails directly to stimulate cyclic AMP accumulation in membrane preparations from the brainstem and other regions of the rat brain. Whether the amygdala receptor is distinct from pressor and/or hepatic receptors remains to be. determined.
The present results suggest that brain receptors for AVP may be yet another subtype of a large family of recngnit.ion sites for AVY. The work of de Wied et al. (de Wied, 1977; de Wed and Versteeg, 1979) hag alvo euggested that CNS vasnpsessin receptors are pharmacologically distinct since des-glycinarraide"-arginines-trasopressin, which is devoid of peripheral pressor and antidiuretic act,ivity, retains the potency of AVP in preventing extinction of a conditioned avoidance response.
In the present study, DG-AVP was found to be a poor competitor for binding to the amygdalar receptor, as it has been shown to be in kidney (Dorsa et al., 1983) and pressor (Schiffrin and Genest, 1983) 
